RenovoRx Expands RenovoCath Adoption to Nine U.S. Cancer Centers
I'm PortAI, I can summarize articles.
RenovoRx Inc. has expanded the adoption of its RenovoCath drug-delivery device to nine U.S. cancer centers, up from five in September 2025. New centers include City of Hope in California and Moffitt in Florida. This growth does not account for centers in the ongoing Phase III TIGeR-PaC trial, which may become commercial customers after enrollment. The company aims for revenue growth in 2026 through a dedicated commercial team and increased physician demand.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments